Determination of volatile organic compounds in exhaled breath of heart failure patients by needle trap micro-extraction coupled with gas chromatography-tandem mass spectrometry
Determination of volatile organic compounds in exhaled breath of heart failure patients by needle trap micro-extraction coupled with gas chromatography-tandem mass spectrometry
复制标题
DOI：
10.1088/1752-7163/aa94e7
复制
发表时间：
2017-12-01
影响因子：
3.8
通讯作者：
Di Francesco, F.
中科院分区：
文献类型：
--
作者：
Biagini, D.;Lomonaco, T.;Di Francesco, F.
通过分析属于属于不同化学类别的22个代表性的呼吸挥发性有机化合物（VOC）的混合物，评估了与气相色谱串联质谱法的针头陷阱微萃取（NTME）的分析性能，该性能评估，芳香和硫磺）。 NTME是一种新兴技术，可通过预先降低小体积样品来确保PPTV范围内的检测极限，并且特别适合呼吸分析。对于大多数VOC，通过以15 mL最小值（-1）的流速为25 mL的25 ml加湿标准气体混合物预先浓缩25 mL（-1），可获得20至500 PPTV的检测极限。对于所有化合物，日期和日内精度始终低于15％，证实了该方法的可靠性。该程序成功地应用于对PISA大学医院期间40名患者收集的呼出呼吸样本。与入院（急性期）相比，大多数患者（约80％）在出院时显示出呼吸丙酮水平显着降低（3倍或更高），这与住院期间改善的临床状况相对应HF加剧的生物标志物。
The analytical performances of needle trap micro-extraction (NTME) coupled with gas chromatography-tandem mass spectrometry were evaluated by analyzing a mixture of twenty-two representative breath volatile organic compounds (VOCs) belonging to different chemical classes (i.e. hydrocarbons, ketones, aldehydes, aromatics and sulfurs). NTME is an emerging technique that guarantees detection limits in the pptv range by pre-concentrating low volumes of sample, and it is particularly suitable for breath analysis. For most VOCs, detection limits between 20 and 500 pptv were obtained by pre-concentrating 25 ml of a humidified standard gas mixture at a flow rate of 15 ml min(-1). For all compounds, inter- and intra-day precisions were always below 15%, confirming the reliability of the method. The procedure was successfully applied to the analysis of exhaled breath samples collected from forty heart failure (HF) patients during their stay in the University Hospital of Pisa. The majority of patients (about 80%) showed a significant decrease of breath acetone levels (a factor of 3 or higher) at discharge compared to admission (acute phase) in correspondence to the improved clinical conditions during hospitalization, thus making this compound eligible as a biomarker of HF exacerbation.